| 摘要 |
<p>The invention is directed to compounds of Formula (I), described herein, as well as pharmaceutically acceptable salts thereof, which act as CRF<sub>1</sub> antagonists and are useful in the treatment of disorders and diseases associated with CRF<sub>1</sub> receptors, including CNS- related disorders and diseases.</p> |
